Paediatric indication for Xolair

on the 1 October 2009

The licence for Xolair (omalizumab), which is indicated for add-on therapy in severe persistent allergic IgE-mediated asthma, has been extended to include children as young as six years.

View Xolair drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Prescribers alerted to topical steroid withdrawal reactions

Prescribers alerted to topical steroid withdrawal reactions

The MHRA has issued advice for prescribers to minimise...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...